CA1323567C - Method for purification of antibodies - Google Patents
Method for purification of antibodiesInfo
- Publication number
- CA1323567C CA1323567C CA000548559A CA548559A CA1323567C CA 1323567 C CA1323567 C CA 1323567C CA 000548559 A CA000548559 A CA 000548559A CA 548559 A CA548559 A CA 548559A CA 1323567 C CA1323567 C CA 1323567C
- Authority
- CA
- Canada
- Prior art keywords
- antibody
- matrix
- column
- releasing agent
- desalting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims description 15
- 238000000746 purification Methods 0.000 title abstract description 13
- 239000011159 matrix material Substances 0.000 claims abstract description 43
- 238000011033 desalting Methods 0.000 claims abstract description 19
- 239000003795 chemical substances by application Substances 0.000 claims description 24
- 239000012062 aqueous buffer Substances 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004202 carbamide Substances 0.000 claims description 2
- 229960000789 guanidine hydrochloride Drugs 0.000 claims description 2
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 claims description 2
- ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 claims description 2
- 229940116357 potassium thiocyanate Drugs 0.000 claims description 2
- VGTPCRGMBIAPIM-UHFFFAOYSA-M sodium thiocyanate Chemical compound [Na+].[S-]C#N VGTPCRGMBIAPIM-UHFFFAOYSA-M 0.000 claims 1
- 229940045136 urea Drugs 0.000 claims 1
- 238000001042 affinity chromatography Methods 0.000 abstract description 3
- 239000000499 gel Substances 0.000 description 12
- 239000000872 buffer Substances 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 229910021538 borax Inorganic materials 0.000 description 6
- 235000010339 sodium tetraborate Nutrition 0.000 description 6
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 6
- 238000000926 separation method Methods 0.000 description 5
- 206010003445 Ascites Diseases 0.000 description 4
- 229920002307 Dextran Polymers 0.000 description 4
- 229920005654 Sephadex Polymers 0.000 description 4
- 239000012507 Sephadex™ Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000000727 fraction Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229940070376 protein Drugs 0.000 description 1
- -1 salt ions Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Control Of El Displays (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Abstract
ABSTRACT OF THE DISCLOSURE
I(g)G3 antibody is purified by affinity chromato-graphy and collection of released antibody at a pH of 9.0 to 9.6. The purification is effected in a column containing both an affinity matrix and a desalting matrix, with the column being equilibrated to a pH of from 9.0 to 9.6.
I(g)G3 antibody may be stored at pH 9.0 to 9.6.
I(g)G3 antibody is purified by affinity chromato-graphy and collection of released antibody at a pH of 9.0 to 9.6. The purification is effected in a column containing both an affinity matrix and a desalting matrix, with the column being equilibrated to a pH of from 9.0 to 9.6.
I(g)G3 antibody may be stored at pH 9.0 to 9.6.
Description
/3650 ~ ~ PURIFICATION OF AN~I~ODIES 1 323567 DP-1031 ~
This invention relates to antibodies, and more par-ticularly to the purification of antibodies. Still more par-ticularly, this invention relates to the purification and storage of antibodies of subclass I(g)G3.
Various methods have been previously employed for purification of antibodies. For example, antibodies have been purified by antigen affinity chromatography or protein A affi-nity chromatography. In attempting to purify antibodies of subclass I(g)G3, difficulties have been encountered in that in such methods the I(g)G3 antibody often precipitates from solu-tion, with such precipitates generally becoming irreversibly insoluble thereby causing loss of purified antibody.
The present invention is directed to improving the purification and storage of antibodies, and in particular, antibodies of subclass I(g)G3.
In accordance with one aspect of the present inven-tion, antibody of subclass I(g)G3 is purified by contacting an affinity matrix with a liquid containing I(g)G3 antibody, with such contacting being effected at a pH of from I 9.0 to 9.6 to bind I(g)G3 antibody on the matrix. Subse-quently, I(g)G3 antibody is released from the matrix, with the I(g)G3 being collected in a liquid buffered to a pH of from 9.0 to 9.6, and most generally at a pH of approximately 9.3.
The antibody is released from the affinity matrix by use of a releasing agent and the I(g)G3 antibody is immediately separ-ated from the releasing agent and collected in an aqueous buffer which is at a pH of from 9.0 to 9.6.
,1 ~
In accordance with a particular~y2 3pr5e6fe7rre~~em~o~r-ment, the affinity matrix is employed in a column, with the column also containing a desalting matrix, with the affinity matrix being positioned at a point in the column which is above the desalting matrix or gel. In this manner, the released antibody passes into the desalting matrix or gel wherein the releasing agent is separated from the I(g)G3 antibody.
The column is equilibrated to a pH of from 9.0 to 9.6, whereby during the purification, the antibody is maintained at this pH and contact between the antibody and the releasing agent is minimized.
Thus, in accordance with another aspect of the pre-sent invention, there is provided a column for purifying anti- ¦
bodies of subclass I(g)G3, wherein the column contains both an affinity matrix and a desalting matrix or gel, with the affin-ity matrix being placed in the column above the desalting gel, with the entire column being equilibrated to a pH of from 9.0 to 9.6, and most generally a pH of about 9.3.
The antibody of subclass I(g)G3 which is purified in accordance with the present invention may be present as part , of a polyclonal antibody or, in accordance with a preferred as-pect of the present invention, the antibody which is purified is a monoclonal antibody of subclass I(g)G3. Thus, if the antibody is a polyclonal antibody, the antibody which is puri-fied may contain antibodies other than I(g)G3 antibody and/or may contain more than one antibody of subclass I(g)G3.
The antibody of subclass I(g)G3 which is purified in accordance with the present invention may be obtained by any one of a wide variety of procedures and may be any one of a wide variety of antibodies. As hereinabove indicated, ll - : ",.
1 323567 ~
the I(g)G3 antibody is preferably a monoclonal antibody. The procedures for preparing monoclonal antibodies are generally known in the art and such antibodies may be purified in accord-ance with the present invention.
The affinity matrix which is employed is one which is capable of adsorbing I(g)G3 antibody. Thus, for example, the affinity matrix may include protein A; an antigen for the I~g)G3 antibody which is to be purified, or an antibody for the I(g)G3 antibody which is to be purified, in an immobilized form (supported on a solid support, such as, for example, cross-linked dextran). m e selection of a suitable affinity matrix for adsorbing I(g)G3 antibody is deemed to be within the scope of those skilled in the art from the teachings herein; accord-ingly, no further details in this respect are deemed necessary to enable those skilled in the art to practice the present in-vention.
The desalting matrix or gel which is employed in the present invention is any one of a wide variety of matrices which are suitable for desalting (separation of small salt ions or m~le-cules from larger m~lecules). Such matrices are often referred to as gels and the procedure employina such matrices is often re-ferred to as gel filtration. In accordance with the present invention, the desaltins matrix is employed to provide a separ-ation between I(g)G3 antibodv released from the affinity matrix and the material or materials which are used for releasing I(g)G3 antibody from the affinity matrix. As representative examples of such desalting matrices, there may be mentioned: ;
crosslinked dextran (for example, of the type sold-under the mark "Sephadex G-25*~1)and polyacrylamide beads (for example, of the type sold under the mark "Bio-~ad P-2*).
*Trademark _3 he column may be equilibrated to a pH WnlCn ~5 at least 9.0 and which is no greater than 9.6 by use of a wide variety of buffers and the selection of a suitable buffer is deemed to be within the scope of those skilled in the art from the teachings herein. For example, the buffer may be-a sodium bicarbonate, a sodium borate or a Tris buffer. A
representative buffer is O.lM sodium borate buffer which pro-vides a pH of about 9.3.
The releasing agent which is employed for releasing antibody from the affinity matrix may be any one of a variety of such releasing agents. In general, such releasing agents are aqueous buffers buffered to a pH of no greater than 4Ø
In st cases, the buffer does not have a pH of less than 2.0;
however, it is to be understood that a lower pH may be em-ployed. The releasing agent could be a chaotropic agent (for example, sodium or potassium thiocyanate); a denaturant such as guanidine hydrochloride or urea, etc. The selection of a suitable releasing agent is deemed to be within the scope of those skilled in the art from the teachings herein.
As hereinabove indicated, in accordance with the present invention, contact between antibody and the releasing agent is minimized, and during purification by use of an affinity matrix, the antibody is maintained and collected at a pH of no less than about 9.0 and no greater than about 9.6.
The present invention will be further described with respect to the accompanying drawing, wherein:
The drawing is a schematic diagram of a chromato-graphic column in accordance with the present invention.
Referring now to the drawing, there is shown a _4_ chromatographic column 10, which includes a desaltlng-gel 11, and an affinity gel 12 layered above the desalting gel 11. -As hereinabove described, the affinity gel is preferably pro-tein A, and the desalting gel is preferably Sephadex.
The column is generally formed in a manner such that the volume of the desalting matrix 11 is at least two times, and preferably at least four times, the volume of the affinity matrix 12. The difference in volume enhances the rapid separ-ation between the releasing agent and the released antibody in the desalting gel 11.
The column 10 is equilibrated to a pH of at least 9.0 and no greater than 9.6, as hereinabove described.
! A sample containing I(g)G3 antibody is introduced into the top of column 10. The sample may be sera, tissue culture media, ascites fluid, etc. The sample preferably con-tains monoclonal antibody of subclass l(g)G3. The sample may be added as is or may be a clarified supernate.
I The antibody is adsorbed on affinity matrix 12 and ` the column is washed with an aqueous buffer which is at a pH
of at least 9.0 and no greater than 9.6.
; After washing, a releasing agent is added to the top of Column 10; for example, an aqeuous buffer which is at a pH of no greater than 4Ø The change in pH releases the antibody from the affinity matrix 12, and the released antibody migrates ahead of the releasing agent into the desalting matrix 11 wherein the released antibody, in the aqueous buffer which is at the pre-equilibrated pH of at least 9.0 and no greater than 9.6 is separated from the releasing agent. In this manner, contact between the released antibody and the releasing agent I
:
is minimized and the antLbody is effectively maintalned at a pH of at least 9.0 and no greater than 9.6 during purification ¦-on Column 10.
The volume of releasing agent which lS added to Column 10 is controlled so as to permit both release of the antibody from the affinity matrix and separation of the re-leased antibody from the releaslng agent, while maintaining the antibody at a pH of at least 9.0 and no greater than 9.6.
Thus, for example, the releasing agent may be added in a volume which is one to two times the volume of the affinity matrix 12.
Thus, as should be apparent, the relative volumes of the affinity matrix 12, the desalting matrix 11 and the releasing agent added to the column are controlled to provide for separation of released antibody from the releasing agent, and collection of released antibody in an aqueous buffer having I
a pH of at least 9.0 and no greater than 9.6. j The column may be employed as hereinabove described for purification of I(g)G3 antibody and, in particular, mono-clonal antibody of subclass I(g)G3. 1 In accordance with a further aspect of the present iinvention, there is provided a composition containing I(g)G3 antibody in an aqueous buffer having a pH of at least about 9.0 and no greater than about 9.6, and most generally a pH of ' about 9.3. The I(g)G3 antibody may be a monoclonal antibody or may be part of a polyclonal antibody mixture. The use of such an aqueous buffer improves the storage stability of I(g)G3 antibodies.
The invention will be further described with re-spect to the following example; however, the scope of the in-vention is not to be limited thereby:
~ ¦¦ EXAMPLE 1 3 2 3 5 6 7 A column approximately 1 cm in diameter by 30 cm in length (24 ml volume) was used for the purification of an IgG( 3? monoclonal antibody ascites. The column was constructed by first filling it with 19 ml (24 cm) of crosslinked dextran (Sephadex G-25). Protein A supported on crosslinked dextran (Sepharose CL-4B, Sigma P-33gl*) was swollen in distilled water and approximately 5 ml (6 cm) was layered over the Sephadex G-25. The colu~n was pre-equilibrated with several passages of 0.1 M sodium borate (pH 9.3). The ascites mixture was layered on and into the column, and then followed by thorough washing with several column volumes of sodium borate buffer.
This removes any residual proteins derived from the ascites.
After this wash step, 10 ml of 0.1 M sodium citrate (pH 3.5) was layered over the Protein A/Sepharose CL-4B*matrix until all sodium citrate buffer passed into the affinity matrix.
The 0.1 M sodium borate reservoir was reconnected to the col-umn after the sodium citrate buffer passed into the column to elute protein. This step was continued until all the antibody eluted from the column and the column was re-equilibrated with 0.1 M sodium borate at pH 9.3. At this point, the column can be used again for antibody purification. The IgG(3) was eluted in fraction 11 while the citrate buffer eluted in frac-tion 24.
The present invention is particularly advantageous in that it is possible to obtain highly purified antibody in a rapid and reproducible manner, without the problems hereto-fore encountered with respect to irreversible precipitation of antibody. Moreover, the methodology is amenable to auto-mation on computerized and programmable purification systems.
*Trademark -7-~ 1 323567 Furthermore, it is now possible to recover and ¦
store I(g)G3 antibody without the problems heretofore encoun-tered in the art; e.g., without irreversible precipitation of antibody.
These and other advantages should be apparent to ¦
those s lled in the art from the teachlngs herein.
1~
., , :
.
, - -:
This invention relates to antibodies, and more par-ticularly to the purification of antibodies. Still more par-ticularly, this invention relates to the purification and storage of antibodies of subclass I(g)G3.
Various methods have been previously employed for purification of antibodies. For example, antibodies have been purified by antigen affinity chromatography or protein A affi-nity chromatography. In attempting to purify antibodies of subclass I(g)G3, difficulties have been encountered in that in such methods the I(g)G3 antibody often precipitates from solu-tion, with such precipitates generally becoming irreversibly insoluble thereby causing loss of purified antibody.
The present invention is directed to improving the purification and storage of antibodies, and in particular, antibodies of subclass I(g)G3.
In accordance with one aspect of the present inven-tion, antibody of subclass I(g)G3 is purified by contacting an affinity matrix with a liquid containing I(g)G3 antibody, with such contacting being effected at a pH of from I 9.0 to 9.6 to bind I(g)G3 antibody on the matrix. Subse-quently, I(g)G3 antibody is released from the matrix, with the I(g)G3 being collected in a liquid buffered to a pH of from 9.0 to 9.6, and most generally at a pH of approximately 9.3.
The antibody is released from the affinity matrix by use of a releasing agent and the I(g)G3 antibody is immediately separ-ated from the releasing agent and collected in an aqueous buffer which is at a pH of from 9.0 to 9.6.
,1 ~
In accordance with a particular~y2 3pr5e6fe7rre~~em~o~r-ment, the affinity matrix is employed in a column, with the column also containing a desalting matrix, with the affinity matrix being positioned at a point in the column which is above the desalting matrix or gel. In this manner, the released antibody passes into the desalting matrix or gel wherein the releasing agent is separated from the I(g)G3 antibody.
The column is equilibrated to a pH of from 9.0 to 9.6, whereby during the purification, the antibody is maintained at this pH and contact between the antibody and the releasing agent is minimized.
Thus, in accordance with another aspect of the pre-sent invention, there is provided a column for purifying anti- ¦
bodies of subclass I(g)G3, wherein the column contains both an affinity matrix and a desalting matrix or gel, with the affin-ity matrix being placed in the column above the desalting gel, with the entire column being equilibrated to a pH of from 9.0 to 9.6, and most generally a pH of about 9.3.
The antibody of subclass I(g)G3 which is purified in accordance with the present invention may be present as part , of a polyclonal antibody or, in accordance with a preferred as-pect of the present invention, the antibody which is purified is a monoclonal antibody of subclass I(g)G3. Thus, if the antibody is a polyclonal antibody, the antibody which is puri-fied may contain antibodies other than I(g)G3 antibody and/or may contain more than one antibody of subclass I(g)G3.
The antibody of subclass I(g)G3 which is purified in accordance with the present invention may be obtained by any one of a wide variety of procedures and may be any one of a wide variety of antibodies. As hereinabove indicated, ll - : ",.
1 323567 ~
the I(g)G3 antibody is preferably a monoclonal antibody. The procedures for preparing monoclonal antibodies are generally known in the art and such antibodies may be purified in accord-ance with the present invention.
The affinity matrix which is employed is one which is capable of adsorbing I(g)G3 antibody. Thus, for example, the affinity matrix may include protein A; an antigen for the I~g)G3 antibody which is to be purified, or an antibody for the I(g)G3 antibody which is to be purified, in an immobilized form (supported on a solid support, such as, for example, cross-linked dextran). m e selection of a suitable affinity matrix for adsorbing I(g)G3 antibody is deemed to be within the scope of those skilled in the art from the teachings herein; accord-ingly, no further details in this respect are deemed necessary to enable those skilled in the art to practice the present in-vention.
The desalting matrix or gel which is employed in the present invention is any one of a wide variety of matrices which are suitable for desalting (separation of small salt ions or m~le-cules from larger m~lecules). Such matrices are often referred to as gels and the procedure employina such matrices is often re-ferred to as gel filtration. In accordance with the present invention, the desaltins matrix is employed to provide a separ-ation between I(g)G3 antibodv released from the affinity matrix and the material or materials which are used for releasing I(g)G3 antibody from the affinity matrix. As representative examples of such desalting matrices, there may be mentioned: ;
crosslinked dextran (for example, of the type sold-under the mark "Sephadex G-25*~1)and polyacrylamide beads (for example, of the type sold under the mark "Bio-~ad P-2*).
*Trademark _3 he column may be equilibrated to a pH WnlCn ~5 at least 9.0 and which is no greater than 9.6 by use of a wide variety of buffers and the selection of a suitable buffer is deemed to be within the scope of those skilled in the art from the teachings herein. For example, the buffer may be-a sodium bicarbonate, a sodium borate or a Tris buffer. A
representative buffer is O.lM sodium borate buffer which pro-vides a pH of about 9.3.
The releasing agent which is employed for releasing antibody from the affinity matrix may be any one of a variety of such releasing agents. In general, such releasing agents are aqueous buffers buffered to a pH of no greater than 4Ø
In st cases, the buffer does not have a pH of less than 2.0;
however, it is to be understood that a lower pH may be em-ployed. The releasing agent could be a chaotropic agent (for example, sodium or potassium thiocyanate); a denaturant such as guanidine hydrochloride or urea, etc. The selection of a suitable releasing agent is deemed to be within the scope of those skilled in the art from the teachings herein.
As hereinabove indicated, in accordance with the present invention, contact between antibody and the releasing agent is minimized, and during purification by use of an affinity matrix, the antibody is maintained and collected at a pH of no less than about 9.0 and no greater than about 9.6.
The present invention will be further described with respect to the accompanying drawing, wherein:
The drawing is a schematic diagram of a chromato-graphic column in accordance with the present invention.
Referring now to the drawing, there is shown a _4_ chromatographic column 10, which includes a desaltlng-gel 11, and an affinity gel 12 layered above the desalting gel 11. -As hereinabove described, the affinity gel is preferably pro-tein A, and the desalting gel is preferably Sephadex.
The column is generally formed in a manner such that the volume of the desalting matrix 11 is at least two times, and preferably at least four times, the volume of the affinity matrix 12. The difference in volume enhances the rapid separ-ation between the releasing agent and the released antibody in the desalting gel 11.
The column 10 is equilibrated to a pH of at least 9.0 and no greater than 9.6, as hereinabove described.
! A sample containing I(g)G3 antibody is introduced into the top of column 10. The sample may be sera, tissue culture media, ascites fluid, etc. The sample preferably con-tains monoclonal antibody of subclass l(g)G3. The sample may be added as is or may be a clarified supernate.
I The antibody is adsorbed on affinity matrix 12 and ` the column is washed with an aqueous buffer which is at a pH
of at least 9.0 and no greater than 9.6.
; After washing, a releasing agent is added to the top of Column 10; for example, an aqeuous buffer which is at a pH of no greater than 4Ø The change in pH releases the antibody from the affinity matrix 12, and the released antibody migrates ahead of the releasing agent into the desalting matrix 11 wherein the released antibody, in the aqueous buffer which is at the pre-equilibrated pH of at least 9.0 and no greater than 9.6 is separated from the releasing agent. In this manner, contact between the released antibody and the releasing agent I
:
is minimized and the antLbody is effectively maintalned at a pH of at least 9.0 and no greater than 9.6 during purification ¦-on Column 10.
The volume of releasing agent which lS added to Column 10 is controlled so as to permit both release of the antibody from the affinity matrix and separation of the re-leased antibody from the releaslng agent, while maintaining the antibody at a pH of at least 9.0 and no greater than 9.6.
Thus, for example, the releasing agent may be added in a volume which is one to two times the volume of the affinity matrix 12.
Thus, as should be apparent, the relative volumes of the affinity matrix 12, the desalting matrix 11 and the releasing agent added to the column are controlled to provide for separation of released antibody from the releasing agent, and collection of released antibody in an aqueous buffer having I
a pH of at least 9.0 and no greater than 9.6. j The column may be employed as hereinabove described for purification of I(g)G3 antibody and, in particular, mono-clonal antibody of subclass I(g)G3. 1 In accordance with a further aspect of the present iinvention, there is provided a composition containing I(g)G3 antibody in an aqueous buffer having a pH of at least about 9.0 and no greater than about 9.6, and most generally a pH of ' about 9.3. The I(g)G3 antibody may be a monoclonal antibody or may be part of a polyclonal antibody mixture. The use of such an aqueous buffer improves the storage stability of I(g)G3 antibodies.
The invention will be further described with re-spect to the following example; however, the scope of the in-vention is not to be limited thereby:
~ ¦¦ EXAMPLE 1 3 2 3 5 6 7 A column approximately 1 cm in diameter by 30 cm in length (24 ml volume) was used for the purification of an IgG( 3? monoclonal antibody ascites. The column was constructed by first filling it with 19 ml (24 cm) of crosslinked dextran (Sephadex G-25). Protein A supported on crosslinked dextran (Sepharose CL-4B, Sigma P-33gl*) was swollen in distilled water and approximately 5 ml (6 cm) was layered over the Sephadex G-25. The colu~n was pre-equilibrated with several passages of 0.1 M sodium borate (pH 9.3). The ascites mixture was layered on and into the column, and then followed by thorough washing with several column volumes of sodium borate buffer.
This removes any residual proteins derived from the ascites.
After this wash step, 10 ml of 0.1 M sodium citrate (pH 3.5) was layered over the Protein A/Sepharose CL-4B*matrix until all sodium citrate buffer passed into the affinity matrix.
The 0.1 M sodium borate reservoir was reconnected to the col-umn after the sodium citrate buffer passed into the column to elute protein. This step was continued until all the antibody eluted from the column and the column was re-equilibrated with 0.1 M sodium borate at pH 9.3. At this point, the column can be used again for antibody purification. The IgG(3) was eluted in fraction 11 while the citrate buffer eluted in frac-tion 24.
The present invention is particularly advantageous in that it is possible to obtain highly purified antibody in a rapid and reproducible manner, without the problems hereto-fore encountered with respect to irreversible precipitation of antibody. Moreover, the methodology is amenable to auto-mation on computerized and programmable purification systems.
*Trademark -7-~ 1 323567 Furthermore, it is now possible to recover and ¦
store I(g)G3 antibody without the problems heretofore encoun-tered in the art; e.g., without irreversible precipitation of antibody.
These and other advantages should be apparent to ¦
those s lled in the art from the teachlngs herein.
1~
., , :
.
, - -:
Claims (8)
1. A process for purifying I(g)G3 antibody, comprising:
contacting a liquid containing I(g)G3 antibody with an affinity matrix for I(g)G3 antibody which is maintained at a pH of at least 9.0 and no greater than 9.6 to adsorb I(g)G3 antibody; releasing adsorbed I(g)G3 antibody from the affinity matrix; and collecting released I(g)G3 antibody in an eluate which is at a pH of at least 9.0 and no greater than 9.6.
contacting a liquid containing I(g)G3 antibody with an affinity matrix for I(g)G3 antibody which is maintained at a pH of at least 9.0 and no greater than 9.6 to adsorb I(g)G3 antibody; releasing adsorbed I(g)G3 antibody from the affinity matrix; and collecting released I(g)G3 antibody in an eluate which is at a pH of at least 9.0 and no greater than 9.6.
2. The process of claim 1 wherein the adsorbed I(g)G3 antibody is released into a desalting matrix maintained at a pH of at least 9.0 and no greater than 9.6.
3. The process of claim 2 wherein the adsorbed I(g)G3 antibody is released by contacting the affinity matrix with a releasing agent and separating the releasing agent and released I(g)G3 antibody in the desalting matrix.
4. The process of claim 3 wherein the releasing agent is an aqueous buffer having a pH of no greater than 4Ø
5. The process of claim 3 wherein said releasing agent is selected from the class consisting of sodium thiocyanate, potassium thiocyanate, guanidine hydrochloride, and urea.
6. The process of claim 4 wherein the volume of the desalting matrix is at least two times greater than the volume of the affinity matrix.
7. The process of any one of claims 1, 2, 3, 4, or 6 wherein the I(g)G3 antibody is a monoclonal antibody.
8. The process of claim 2 wherein the pH of the desalting matrix, affinity matrix and eluate is about 9.3.
Priority Applications (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA000548559A CA1323567C (en) | 1987-10-05 | 1987-10-05 | Method for purification of antibodies |
| ES198787308900T ES2041690T3 (en) | 1987-10-05 | 1987-10-07 | METHOD FOR THE PURIFICATION OF ANTIBODIES. |
| EP87308900A EP0310719B1 (en) | 1987-10-05 | 1987-10-07 | Method for purification of antibodies |
| DE8787308900T DE3779125D1 (en) | 1987-10-05 | 1987-10-07 | CLEANING METHOD FOR ANTIBODIES. |
| AT87308900T ATE76082T1 (en) | 1987-10-05 | 1987-10-07 | PURIFICATION METHOD FOR ANTIBODIES. |
| FI874431A FI90082C (en) | 1987-10-05 | 1987-10-08 | Procedure and chromatography column for purification of antibodies |
| AU79556/87A AU600311B2 (en) | 1987-10-05 | 1987-10-12 | Method for purification of antibodies |
| JP62287203A JPH0696598B2 (en) | 1987-10-05 | 1987-11-13 | Antibody purification method |
| GR920400948T GR3004622T3 (en) | 1987-10-05 | 1992-05-18 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA000548559A CA1323567C (en) | 1987-10-05 | 1987-10-05 | Method for purification of antibodies |
| EP87308900A EP0310719B1 (en) | 1987-10-05 | 1987-10-07 | Method for purification of antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1323567C true CA1323567C (en) | 1993-10-26 |
Family
ID=25671537
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000548559A Expired - Fee Related CA1323567C (en) | 1987-10-05 | 1987-10-05 | Method for purification of antibodies |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP0310719B1 (en) |
| JP (1) | JPH0696598B2 (en) |
| AT (1) | ATE76082T1 (en) |
| AU (1) | AU600311B2 (en) |
| CA (1) | CA1323567C (en) |
| DE (1) | DE3779125D1 (en) |
| ES (1) | ES2041690T3 (en) |
| FI (1) | FI90082C (en) |
| GR (1) | GR3004622T3 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5151504A (en) * | 1989-11-17 | 1992-09-29 | E. R. Squibb & Sons, Inc. | Method for purification of monoclonal antibodies |
| DE4118912C1 (en) * | 1991-06-08 | 1992-07-02 | Biotest Pharma Gmbh, 6072 Dreieich, De | |
| US8084032B2 (en) | 2004-01-21 | 2011-12-27 | Ajinomoto Co., Inc. | Purification method which prevents denaturation of an antibody |
| WO2016031932A1 (en) * | 2014-08-27 | 2016-03-03 | 田辺三菱製薬株式会社 | METHOD FOR PRODUCING PROTEIN HAVING Fc REGION BY ALKALI WASHING |
| MX395730B (en) * | 2015-03-13 | 2025-03-25 | Bristol Myers Squibb Co | USE OF ALKALINE WASHES DURING CHROMATOGRAPHY TO REMOVE IMPURITIES. |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1209907A (en) * | 1982-04-12 | 1986-08-19 | Richard M. Bartholomew | Method of affinity purification employing monoclonal antibodies |
| JPS60228421A (en) * | 1984-04-27 | 1985-11-13 | Shionogi & Co Ltd | Monoclonal anti-human-igg antibody and its preparation |
-
1987
- 1987-10-05 CA CA000548559A patent/CA1323567C/en not_active Expired - Fee Related
- 1987-10-07 ES ES198787308900T patent/ES2041690T3/en not_active Expired - Lifetime
- 1987-10-07 EP EP87308900A patent/EP0310719B1/en not_active Expired
- 1987-10-07 AT AT87308900T patent/ATE76082T1/en not_active IP Right Cessation
- 1987-10-07 DE DE8787308900T patent/DE3779125D1/en not_active Expired - Fee Related
- 1987-10-08 FI FI874431A patent/FI90082C/en not_active IP Right Cessation
- 1987-10-12 AU AU79556/87A patent/AU600311B2/en not_active Ceased
- 1987-11-13 JP JP62287203A patent/JPH0696598B2/en not_active Expired - Lifetime
-
1992
- 1992-05-18 GR GR920400948T patent/GR3004622T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ATE76082T1 (en) | 1992-05-15 |
| JPH0696598B2 (en) | 1994-11-30 |
| EP0310719B1 (en) | 1992-05-13 |
| FI90082C (en) | 1993-12-27 |
| FI90082B (en) | 1993-09-15 |
| JPH01135798A (en) | 1989-05-29 |
| AU7955687A (en) | 1989-04-13 |
| EP0310719A1 (en) | 1989-04-12 |
| AU600311B2 (en) | 1990-08-09 |
| FI874431A0 (en) | 1987-10-08 |
| DE3779125D1 (en) | 1992-06-17 |
| GR3004622T3 (en) | 1993-04-28 |
| FI874431L (en) | 1989-04-09 |
| ES2041690T3 (en) | 1993-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0453767B1 (en) | Improved method for purification of monoclonal antibodies | |
| US4704366A (en) | Process for binding IgG to protein A | |
| FI88403C (en) | MONOCLONAL ANTIKROPPAR, FOERFARANDE FOER FRAMSTAELLNING AV DESSA OCH AFFINITETSRENINGSFOERFARANDE VARI DESSA ANVAENDS | |
| Belew et al. | High-performance analytical applications of immobilized metal ion affinity chromatography | |
| CA1339389C (en) | Purified protein a compositions and methods for their preparation | |
| Lihme et al. | Divinylsulphone-activated agarose: formation of stable and non-leaking affinity matrices by immobilization of immunoglobulins and other proteins | |
| EP0368092B1 (en) | Ion exchange and separation method | |
| Katz et al. | Drug residue analysis using immunoaffinity chromatography | |
| Robinson et al. | Nitrocellulose-bound antigen repeatedly used for the affinity purification of specific polyclonal antibodies for screening DNA expression libraries | |
| US4312727A (en) | Glyoxal agarose and zonal immobilization of proteins therewith | |
| CA1323567C (en) | Method for purification of antibodies | |
| US6613884B1 (en) | Method for the removal/purification of serum albumins and means for use in the method | |
| Pak-Leong | Isolation of specific IgM monoclonal antibodies by affinity chromatography using alkaline buffers | |
| Danielsson et al. | One-step purification of monoclonal IgG antibodies from mouse ascites: an evaluation of different adsorption techniques using high performance liquid chromatography | |
| US4841024A (en) | Purification of antibodies | |
| Bridonneau et al. | Behaviour of human immunoglobulin G subclasses on thiophilic gels: comparison with hydrophobic interaction chromatography | |
| Cutler | Affinity chromatography | |
| Zeheb et al. | An analytical method for the selective retrieval of iminobiotin-derivatized plasma membrane proteins | |
| Bøg-Hansen | Separation of monoclonal antibodies from cell-culture supernatants and ascites fluid using thiophilic agarose | |
| Naguib et al. | Purification of Chironex fleckeri venom components using Chironex immunoaffinity chromatography | |
| Abdullah et al. | The application of DNA-cellulose chromatography in the isolation of immunoglobulin M and complement component C4b-binding protein from human serum | |
| JPH02180899A (en) | Method for purifying immunoglobulin | |
| Apter | Immunoaffinity purification of albumin from fish serum | |
| McKinney et al. | Improved immunoadsorption procedure with anion-exchange bacterial cell columns | |
| Novales‐Li | Purification of murine immunoglobulin M from spent tissue culture supernatant by one‐step gel filtration chromatography procedure |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKLA | Lapsed |